Dengue virus (DENV) non-structural protein 4B (NS4B) has been demonstrated to be an attractive antiviral target. Due to its nature as an integral membrane protein, NS4B remains poorly characterized. In this study, we generated and characterized two monoclonal antibodies (mAb) that selectively bind to DENV NS4B protein. One mAb, 10-3-7, is specific for DENV-2 NS4B, and its epitope was mapped to residues 5-15 of NS4B. The other mAb, 44-4-7, cross-reacts with all the four serotypes of DENV NS4B, and its epitope was mapped to residues 141-147 of NS4B. Using the mAbs, we probed the intracellular orientation of the epitopes of NS4B by an epitope accessibility assay. The results showed that the N-terminus of NS4B is located in the ER lumen, whereas amino acids 130-148 of NS4B are located in the cytosol. The study demonstrates that the two anti-NS4B mAbs will be useful for future structural and functional analyses of DENV NS4B.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.virol.2013.12.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epitope-based therapeutic targets in HCV genotype 1 non-structural proteins: a novel strategy to combat emerging drug resistance.
Front Cell Infect Microbiol
November 2024
Department of Infectious Diseases, The First People's Hospital of Kashi Prefecture, Kashi, China.
Introduction: The hepatitis C virus (HCV) poses a major global health challenge, with its non-structural proteins being essential for viral replication and pathogenesis. Mutations in these proteins significantly contribute to drug resistance, necessitating innovative therapeutic strategies. This study aims to identify epitope-based therapeutic targets in the non-structural proteins of HCV genotype 1, employing in-depth in silico tools to counteract emerging drug resistance.
View Article and Find Full Text PDFH, N and C backbone resonance assignment of the N-terminal region of Zika virus NS4B protein in detergent micelles.
Biomol NMR Assign
November 2024
Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Zika virus has raised global concerns due to its link to microcephaly and Guillain-Barré syndrome in adults. One of viral nonstructural proteins-NS4B, an integral membrane protein, plays crucial roles in viral replication by interacting with both viral and host proteins, rendering it an attractive drug target for antiviral development. We purified the N-terminal region of ZIKV NS4B (NS4B NTD) and reconstituted it into detergent micelles.
View Article and Find Full Text PDFInhibitory peptides derived from Hepatitis C virus NS5A for reducing clinical symptoms of dengue virus infection.
Antiviral Res
November 2024
College of Veterinary Medicine and Bio-Safety Research Institute, Jeonbuk National University, Iksan, 54596, Republic of Korea. Electronic address:
Article Synopsis
- Lethal Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) are serious conditions caused by the Dengue virus (DENV), highlighting the need for better treatments.
- Researchers developed and tested five peptides derived from hepatitis C virus (HCV) NS5A, with two (3a 3/20 and DS-05) showing promising antiviral effects against multiple DENV serotypes.
- Animal studies indicated that these peptides improved survival rates, reduced viral loads, and lessened organ damage in mice infected with DENV, suggesting their potential for use in treating severe dengue cases in humans.
Genomic surveillance reveals a dengue 2 virus epidemic lineage with a marked decrease in sensitivity to Mosnodenvir.
Nat Commun
October 2024
Unité des Virus Émergents (Aix-Marseille Université, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
Article Synopsis
- * Recent analysis of dengue virus genomes from the French Caribbean revealed a mutation (NS4B:V91A) associated with reduced sensitivity to mosnodenvir, particularly in the DENV-2 strain, where sensitivity dropped by more than 1000 times.
- * Phylogenetic analysis suggests that the low sensitivity due to the V91A mutation has re-emerged several times over the past 30 years in DENV-2 and DENV-3, highlighting the need for
Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition.
Molecules
August 2024
Institute for Molecules and Materials, Faculty of Science, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
Orthoflaviviruses, including zika (ZIKV), West Nile (WNV), and dengue (DENV) virus, induce severely debilitating infections and contribute significantly to the global disease burden, yet no clinically approved antiviral treatments exist. This review offers a comprehensive analysis of small-molecule drug development targeting orthoflaviviral infections, with a focus on NS2B-NS3 inhibition. We systematically examined clinical trials, preclinical efficacy studies, and modes of action for various viral replication inhibitors, emphasizing allosteric and orthosteric drugs inhibiting NS2B-NS3 protease with in vivo efficacy and in vitro-tested competitive NS2B-NS3 inhibitors with cellular efficacy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!